Coherus Announces Proposed Public Offering of Common Stock
15 mai 2023 16h01 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of...
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
08 mai 2023 16h05 HE
|
Coherus BioSciences, Inc.
– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation –– FDA inspection of...
Coherus BioSciences to Present at Upcoming Investor Conferences in May
04 mai 2023 16h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor...
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
01 mai 2023 16h07 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market...
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
27 avr. 2023 08h05 HE
|
Coherus BioSciences, Inc.
SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
06 mars 2023 16h01 HE
|
Coherus BioSciences, Inc.
– Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 –– FDA is planning the toripalimab manufacturing site inspection in Q2 2023 –– UDENYCA® autoinjector...
FDA Approves UDENYCA® Autoinjector
06 mars 2023 08h00 HE
|
Coherus BioSciences, Inc.
- UDENYCA® is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing...
Coherus BioSciences to Present at Upcoming Investor Conferences in March
01 mars 2023 08h25 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences...
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
28 févr. 2023 08h25 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be...
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
15 févr. 2023 08h25 HE
|
Coherus BioSciences, Inc.
SHANGHAI, China and REDWOOD CITY, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....